Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous serum eye drops 20%
- Development stage
- Phase 4
- Lead developer
- GIANCARLO FATOBENE
- Administration
- Ophthalmic
01
Overview
Autologous serum eye drops (ASED) are a biologic therapy prepared from a patient's own peripheral blood, designed to treat severe ocular surface disorders. The serum serves as a tear substitute, containing high concentrations of epitheliotrophic factors such as epidermal growth factor (EGF), fibroblast growth factor, fibronectin, and vitamin A, which are essential for corneal epithelial health. This specific 20% concentration is being investigated in a Phase 2 pilot trial (NCT07014059) sponsored by Giancarlo Fatobene, which utilizes a closed-circuit collection system to improve accessibility and maintain sterility. The therapy is targeted at chronic conditions including dry eye syndrome, graft-versus-host disease (GVHD), and neurotrophic keratitis, providing anti-inflammatory and regenerative support to the ocular surface.
- Other names
- ASEDAutologous serum 20%Autologous serum eye drops
02
Targets
EGFR (Epidermal growth factor receptor)FGFR (FGFR family)IGF-1R (Insulin-like growth factor 1 receptor)RAR (Retinoic acid receptor)TGFBR (TGF-beta receptor)
Beyond the preview
Go deeper on Autologous serum eye drops 20%.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous serum eye drops 20%.